Safety of Anumigilimab in Adults With Sickle Cell Disease
Tests anumigilimab, given by injection, against placebo in adults with sickle cell disease.
Plain-language title generated from the registry record
Registry title: Safety of Anumigilimab (CSL324) in Adults With Sickle Cell Disease (SCD)
Key facts
- Where
- Amsterdam, NetherlandsSee the site
- Phase
- Phase 2
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with sickle cell disease to test the safety of a new injected medicine called anumigilimab, compared with placebo.
- Age
- 18 years or older
- Sex
- All sexes can join.
- Disease stage
- Confirmed sickle cell disease of any genotype, with 1 to 12 pain crises (VOCs) in the past 12 months that needed a visit to a medical facility and treatment with injected opioids or injected anti-inflammatory pain medicine.
- Earlier treatment
- Either a stable, well-tolerated hydroxyurea (HU) regimen for at least 30 days before screening, or HU stopped or refused. Any other preventive medicine for the disease must have a stable dose for 30 days before screening.
Main reasons for not taking part
- Absolute neutrophil count below 2.5 ×10^9 cells/Litre at screening or baseline
- Dose of a preventive medicine for sickle cell disease not stable in the 30 days before screening
Read by machine on 9 November 2026.
Where in Netherlands
- Amsterdam UMC StichtingAmsterdam, NetherlandsTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- CSL Behring
- Trial code
- NCT07224360EU 2025-521154-42-00
- Record updated
- 3 November 2026
- Original description
This is a phase 2a, global, multicenter, randomized, double-blind, placebo-controlled study investigating the safety of anumigilimab administered subcutaneously (SC) at the maximum tolerated dose (MTD) in adult participants with SCD.Read full original descriptionShow less
Phase 2a, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Assess the Safety of Anumigilimab (CSL324) in Adults With Sickle Cell Disease
This is a phase 2a, global, multicenter, randomized, double-blind, placebo-controlled study investigating the safety of anumigilimab administered subcutaneously (SC) at the maximum tolerated dose (MTD) in adult participants with SCD.
The primary aim of the study is to assess the safety of anumigilimab in participants with SCD. Participants will be treated for 64 weeks: for 12 weeks in the dose escalation period, where the dose will be escalated to each participant's individual MTD; and for 52 weeks at the MTD in the maintenance period.
Inclusion: Adults aged greater than or equal to (>=) 18 years on the day of signing the informed consent form; Confirmed diagnosis of SCD of any genotype; Experienced 1 to 12 VOCs requiring a visit to a medical facility and treatment with parenteral opioids or a parenteral nonsteroidal anti-inflammatory drug within the 12 months before Screening; HU Regimen:; a. On stable and well-tolerated Hydroxyurea (HU) regimen for at least 30 days before Screening; or; b. HU was discontinued or refused (eg, due to concern of side effects or lack of effect).
Exclusion: If on SCD preventive medication, dose is not stable in the 30 days before Screening; Absolute neutrophil count less than (<) 2.5 ×10\^9 cells/Litre at Screening or Baseline (Week 1 Day 1).